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Introduction: We reviewed our experience with immunosuppressive agents in patients with
steroid-resistant Interstitial Lung Disease in the setting of Polymyositis/Dermatomyositis
(PM/DM-ILD) to determine whether there were major differences in outcomes.
Methods: We identified all patients treated for PM/DM-ILD and assessed cyclophosphamide
(CYC), azathioprine (AZA) and mycophenolate (MMF) when used as first-line steroid sparing
therapy for effects on pulmonary function variables, dyspnea and tolerance at six and twelve
months.
Results: Among 46 patients meeting the inclusion criteria, 24 were treated with CYC, 13 with
AZA and 9 with MMF. There were no baseline differences between the three treatment groups
for any of the demographic or physiologic variables, dyspnea score, the presence of >30%
fibrosis on CT, or the baseline steroid dose. At the six months assessment, the overall median
change in FVC was 5.0% (25th, 75th percentile 3, 11.5%), corresponding to þ.20 L (.09,
0.42 L) and the DLCO increased by 2.93% (4, 9%), corresponding to 1 mm/ml/Hg (.58,
2.3). The severity of dyspnea decreased substantially, prednisone dose could be reduced
and no important difference in side effects was found in the whole group of patients. This ef-
fect was sustained after twelve months of therapy.1 216 444 4707.
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ated with stabilization of pulmonary physiology, improved dyspnea, and a reduction of steroid
dose.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Interstitial lung disease (ILD) occurs in nearly 40% of in-
dividuals with polymyositis-dermatomyositis (PM-MD),
though prevalence reported in individual series has varied
widely.2,10e14 The presence of ILD confers a high risk of
death, with estimated mortality around 30%.2,13,14 Prog-
nostic factors that have been associated with poor out-
comes include acute onset, steroid-refractoriness and more
severe impairment of pulmonary physiology.2,11e14
The treatment for patients with PM/DM ILD is largely
based on case reports and smallcase series that describe
benefits from a wide range of immunosuppressants. Intra-
venous cyclophosphamide (CYC) has been advocated as the
appropriate initial approach for patients with steroid-
refractory severe ILD,3 where it is used in combination
with high doses of corticosteroids. Oral CYC is commonly
believed to be effective based on extrapolation from the
experience with intravenous CYC and analogy with other
rheumatologic conditions, but there are no published data
supporting its utility. Methotrexate has been used as well,
but concerns about distinguishing toxicity from disease
progression limit enthusiasm for it.
Azathioprine has historically been the most widely used
steroid-sparing medication, for patients with more moder-
ate disease or for maintenance therapy after induction with
CYC.4,5 However, there are no controlled data about out-
comes compared with other agents. More recently, myco-
phenolate (MMF) was proposed as a viable alternative
therapy.5,6,30
It is clear that larger experiences are necessary to
delineate the expected response to commonly used thera-
pies in PM/DM ILD. To that end, we retrospectively
analyzed our patients with PM/DM ILD who were treated
with steroid-sparing agents in our clinic.
Materials and methods
We identified all outpatients treated for PM/DM ILD who
had adequate longitudinal follow-up and for whom we were
the first physicians to start cyclophosphamide (CYC),
azathioprine (AZA) or mycophenolate mofetil (MMF). PM/
DM as a cause of the ILD was considered to be present in
patients fulfilling the definite or probable diagnostic
criteria defined by Bohan and Peter,1,7 and who had no
other ascertainable cause for their ILD. We also included
patients with features of the antisynthetase syndrome and
no other identifiable cause for the lung disease (anti-
myositis antibodies other than Anti-Jo were available in
only 8 of our patients, with a positive anti-PL12 in one). We
excluded patients with predominant scleroderma features,
since therapy for those individuals was based on the find-
ings from the Scleroderma Lung Study.3 Patients with otherconnective tissue diseases and overlap syndromes were also
excluded.
All the patients were selected to receive immunosup-
pressive agents due to persistently bothersome pulmonary
disease despite treatment with steroids, or marked symp-
toms in the context of abnormal pulmonary function
testing. Only patients who had been treated with steroid-
sparing medications, and who had longitudinal follow-up
for at least six months in our clinic were included. The
study period spanned the years 2003e2010. This protocol
was approved by the Cleveland Clinic Institutional Review
Board (IRB# 11e499).
We routinely obtained demographic and disease-related
features at the time of the initial visit, or when the diag-
nosis of PM/DM ILD was first made in the pulmonary clinic.
All patients had chest CT performed at our institution at the
time of the initial evaluation, using a standard protocol.
Specifically, all CTs were obtained with no contrast and
1 mm collimation during an inspiratory breath hold with a
64-head scanner. A chest radiologist (RY) graded the pro-
portion of subjects with fibrosis encompassing more than
30% of the lung parenchyma according to the method pro-
posed by Goh.8
Pulmonary function testing was reported using reference
equations derived from Hankinson.9 We routinely assessed
dyspnea at each visit in our clinic using the Modified Medical
Research Council (MMRC) Dyspnea Scale. Toxicity de-
terminations were graded according to the revised Common
Terminology Criteria for Adverse Events v3.0 (CTCAE)
schema. The data were analyzed by Wilcoxon Rank Sum
Test or ChieSquare Test, as appropriate.
The choice of medication was made by the treating
physician. We assessed the effect of the medications at 6
and 12 months on forced vital capacity (FVC), diffusing
capacity for carbon monoxide (DLCO), dyspnea, prednisone
dose and tolerance. Two patients were intolerant of
azathioprine within two months of starting it, and were
switched to MMF. These two patients were analyzed after
six months of the new medication, using the time of
starting the new medication as a baseline value. One other
patient stopped medication prior to six months due to
pneumonia (MMF) and was lost to follow-up. This patient
was not included in the outcomes.Results
Clinical features
One hundred fifty-three patients were diagnosed with
PM/DM but only forty-six patients met the inclusion
criteria. The reasons for exclusion included insufficient
evidence of ILD (42 patients), lack of adequate follow-up,22
predominant scleroderma features,21 use of other
892 I.C. Mira-Avendano et al.immunosuppressive medications14 and no new immuno-
suppressive treatment rendered.8
The duration of PM/DM symptoms before the diagnosis of
ILD was less than six months in 15 (33%) patients, seven to
twelve months in 12 (27%), thirteen to twenty-four months
in six (11%), twenty-five to thirty-six months in nine (20%)
and more than thirty-six months in three (7%). In only one
case, ILD was diagnosed one year before the evidence of
PM/DM symptoms. The duration of PM/DM symptoms did
not impact grade of dyspnea, FVC or DLCO in our group of
patients.
The baseline characteristics are listed in Table 1. Most of
the patients (74%) had polymyositis; the remaining 26% had
dermatomyositis. The median age was 53 years; 26 (57%)
were females, and 37 (81%) were Caucasian. There was a
trend (p Z 0.06) for females to be treated with agents
other than AZA, and former smokers were more likely to be
treated with CYC (p Z 0.03). Fibrosis encompassing more
than 30% of the lung parenchyma on HRCTwas present in 24
(52%) of the subjects. Specific radiologic patterns suggested
by the HRCT included predominant organizing pneumonia in
17 patients (37%), NSIP in 16 (35%), UIP in 9 (19%) and a
mixed pattern in 4 (9%) of the patients.
The median baseline prednisone dose for the entire
population was 40mg/d (25th, 75th percentile 28, 53mg/d).
At the time of our first evaluation, 39 (85%) of the patients
were considered steroid-resistant (taking 20 mg/d of
prednisone for at least three months), 10 of whom were
taking methotrexate plus prednisone. These patients had
generally been treated with starting prednisone doses
ranging from 40 to 80 mg daily, without adequate control of
their ILD. In the remaining seven patients, we started pred-
nisone and the steroid-sparing agent contemporaneously.
Notable clinical features at the time we evaluated the
patients included cough in 45 (98%) of the patients and
symptomatic muscle weakness in 12 (26%). When muscle
enzyme levels were determined, 21/40 (53%) had elevated
creatinine kinase levels, with 11 (28%) more than 5-fold the
upper limit of normal. Aldolase, was elevated in 14 of 32
cases (43%). Anti-Jo1 antibody was positive in 50% of theTable 1 Baseline features.
Variable Cyclophosphamide
(n Z 24)
Age 56 (52.65)
Female gender 15 (63%)
White racea 18 (78%)
Former smokerb 17 (71%)
Anti-Jo1 11 (46%)
HRCT: 30% Fibrosis 12 (50%)
Dyspnea
Grade 2 2 (8%)
Grade 3 11 (46%)
Grade 4 11 (46%)
FVC (%) 58 (48.78)
DLCO (%) 45 (34.58)
Baseline steroid dose 40 (22.40)
All values are median (25th, 75th percentile) except where specified
a Fewer than 46 patients included due to missing data.
b No patient was a current smoker.patients, and mechanic’s hands were present in 46%,
including 16 patients with both, who were thereby diag-
nosed with suspected antisynthetase syndrome (34% of the
whole case series). Thus, the presence of mechanics hands
conferred a high likelihood of anti-Jo 1 seropostivity.
Bronchoscopy with bronchoalveolar lavage was per-
formed in 24 patients, usually to exclude infection.
Elevated neutrophils (>3%) were present in 16 subjects
(67%), elevated lymphocytes (>15%) in 11 (45%) and eo-
sinophils (>1%) in 5 (21%). None of the 24 subjects were
found to have infections. Among 16 patients with surgical
lung biopsies, ten cases were available for review by a
pulmonary pathologist (VA). These included nonspecific
interstitial pneumonia (NSIP, 5 cases) and one case each of
organizing pneumonia, diffuse alveolar damage, and non-
diagnostic biopsy. Two patients had substantial features of
both NSIP and OP. The other six cases were reported as a
NSIP (five) or OP.1 No foamy macrophages on BAL or sug-
gestion of aspiration pneumonia on lung biopsy (bronchio-
litis, giant cells) were seen. The outcomes among these 16
patients were not significantly different, but the numbers
are too small to be conclusive.Effect of treatment
The initial steroid-sparing regimen was selected at the
discretion of the primary pulmonologist. There were no
significant differences in prescribing pattern according to
treating physician, either in terms of frequency of medi-
cation use or severity of the lung disease as measured by
FVC. We do not typically use methotrexate in this setting,
although it has been reported to be effective,14 due to
concern about potential toxicity masquerading as ILD pro-
gression. There were no differences between the three
treatment groups for any of the demographic or physiologic
variables, the presence of >30% fibrosis on CT, or the
baseline steroid dose.
For the first six months, 24 patients received CYC, 13
received AZA and 9 received MMF. The average dose wasAzathioprine
(n Z 13)
Mycophenolate
(n Z 9)
P value
50 (46.64) 56 (47.64) .36
4 (31%) 7 (78%) .06
9 (75% 9 (100%) .30
7 (78%) 2 (22%) .04
7 (54%) 5 (56%) .91
9 (69%) 3 (33%) .26
.32
2 (15%) 0 (0)
3 (23%) 7 (78%)
8 (61%) 2 (22%)
63 (47.78) 64 (55.78) .76
53 (43.61) 58 (47.64) .17
40 (28.60) 40 (35.60) .44
.
Figure 2 Percentage DLCO after 6 and 12 months of
treatment.
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MMF. At the six months assessment, the overall median
change in FVC was 5.0% (25th, 75th percentile 3, 11.5%),
corresponding to þ.20 L (.09, 0.42 L) and the DLCO
increased by 2.93% (4, 9%), corresponding to 1 mm/ml/Hg
(.58, 2.3). For the 33 patients who remained on consistent
therapy for 12 months, the median change in FVC was 4.7%
(.5, 9.5%), or þ.2 L (.04, 0.38 L). The DLCO had increased
from baseline by 2.3% (5, 7%), or .61 (1.19, 2.1) mm/ml/
Hg (Figs. 1 and 2).
In the whole case series, MMRC dyspnea grade >2 was
present in 92% of patients at the beginning of treatment,
but in only 26% at 6 months and 40% at 12 months (Table 2).
The prednisone dose was reduced from 40 mg/d to a me-
dian dose of 10 mg/d (7.5, 20), 16.3 mg/d (1.25, 20) and
15 mg/d10,20 at six months and 7.5 mg/d (0, 12.5), 7.5 mg/
d (0, 20) and 10 (0, 17.5) at 12 months, in the CYC, AZA and
MMF group, respectively.
None of these outcomes were statistically associated
with the choice of therapy.
In 13 patients, a second agent was substituted at 6
months after the first one. The reasons for switching
medications included toxicity (two patients), concern
about potential CYC toxicity (6 patients) and inadequate
response (5 patients). This group comprised 10 patients
treated initially with CYC; four were switched to AZA and 6
to MMF. AZA was the first drug in two cases, followed by
CYC in both, and MMF was the first medication used in one
patient, followed by AZA. Analysis of the effect of the
second medication on FVC and DLCO 6 months after starting
it, demonstrated that the detected values after the first
drug were maintained without any significant change,
remaining improved in the eight patients in whom toxicity
developed. In the five patients who did not have an
adequate response to a first agent, the second agent like-
wise did not improve the physiologic variables after six
months.
Grade 3 medication toxicity, requiring interruption of
the immunosuppressive agent occurred in one patient in
the CYC group (invasive pulmonary aspergillosis). Other
toxic effects, classified as Grade 1 and 2, occurred in 11
(48%), 3 (23%) and 4 (44%) of the CYC, AZA and MMF groups,
respectively, without need for drug discontinuation.Figure 1 FVC percentage after 6 and 12 months of treatment
with the three different medications.After a median follow-up of 5.1 years since our initial
evaluation, 39 patients (85%) are still living. Three required
lung transplantation: two are alive at two years and at two
months post-transplantation, respectively; one died three
weeks after transplantation from post-operative compli-
cations. The other deaths were due to advanced primary
lung disease in two cases, for unknown reasons in three
cases and from septic shock in a patient no longer on
immunosuppressive medication.
Discussion
Our experience suggests that cyclophosphamide, azathio-
prine, and mycophenolate mofetil are similarly viable al-
ternatives for initial steroid-sparing therapy of PM/DM ILD.
In our population, use of any of the three agents was
associated with a stabilization of pulmonary function tests,
less dyspnea, and a substantial reduction of the steroid
dose. The benefits of treatment persisted over at least 12
months. In addition, the effects of treatment did not
appear to be influenced by the extent of parenchymal
fibrosis as assessed by the baseline chest CT study.
In eight patients who were changed to a second agent
due to toxicity or side effects, the response to the second
agent was similar. For five patients who were thought to
have an inadequate response to the initial steroid-sparing
therapy, switching to a second agent was not noticeably
helpful. This could indicate that the benefits of substitute
agents do not go beyond avoiding toxicity, but our numbers
are too small to derive conclusions.
The usefulness of CYC and CYC-containing regimens was
first described more than two decades ago in patients with
acute presentations of PM/DM ILD associated with respira-
tory failure.24,25,27 In a small prospective cohort study, ten
patients with acute interstitial pneumonia in the setting of
DM were treated with combined intravenous CYC, cyclo-
sporine A (CSA) and intravenous corticosteroids. Compared
with historical controls treated with CSA alone, the com-
bination regimen reduced mortality from 90 to 50%.26 In
2007, Yamasaki et al. reported that intravenous CYC
reduced dyspnea and/or improved pulmonary function in 12
of 17 patients.28 In general, CYC has been reserved for
patients with severe disease and acute or subacute onset of
Table 2 Effect of treatment.
Variable Cyclophosphamide
(n Z 24)
Azathioprine
(n Z 13)
Mycophenolate
(n Z 9)
P value
FVC 6 months % 66 (55.87) 59 (53.80) 67 (57.90) .61
FVC 12 months % 67 (51.79) 61 (52.85) 64 (52.81) .92
DLCO 6 months % 50 (40.64) 54 (44.65) 64 (58.69) .20
DLCO 12 months % 46 (39.61) 61 (38.74) 63 (50.64) .17
Dyspnea 6 monthsa .49
Grade 2 13 (59%) 8 (72%) 8 (88%)
Grade 3 8 (36%) 3 (27%) 1 (11%)
Grade 4 1 (5%) 0 0
Dyspnea 12 monthsa .62
Grade 2 11 (57%) 5 (40%) 4 (80%)
Grade 3 6 (31%) 6 (60%) 1 (20%)
Grade 4 2 (11%) 0 0
Prednisone dose at 6 months 10 (8.20) 16 (1.20) 15 (10.20) .44
Prednisone at 12 months. 8 (0.13) 8 (0.20) 10 (0.18) .86
Toxicity 12 (50%) 3 (23%) 4 (44%) .52
All values are median (25th, 75th percentile) except where specified.
a Fewer than 46 patients included due to missing data.
894 I.C. Mira-Avendano et al.ILD. Our experience is the first report that oral CYC is useful
for PM/DM ILD, but does not support the hypothesis that
oral CYC in this setting is more effective than less toxic
medications.
The current data supporting the benefits of azathioprine
are limited to small case series and case reports16,23,29
where it was used for maintenance therapy after induc-
tion or for patients with milder ILD. There are no large
series documenting the expected response to azathioprine.
In a review of 160 patients with DM/PM, including 23% with
ILD, AZA and methotrexate appeared to exhibit generally
similar effectiveness, though the authors did not specif-
ically analyze the effects on lung disease. Recently,
mycophenolate was shown to be effective in general for
CTD-associated ILD, in a study that included five patients
with PM/DM.30 A subsequent study reported that MMF
improved pulmonary physiology, dyspnea and steroid re-
quirements in three of four patients.31
Benefits from other agents have also been described in
small case series, including cyclosporine for steroid-
resistant pneumonitis,20e22 tacrolimus,32e34 leflunomide,35
intravenous immunoglobulin36 and rituximab.37 We
excluded analysis of those agents, since they were gener-
ally used in small number of patients, or for 3rd or 4th line
therapy.
The clinical characteristics of our population resemble
those described by prior authors. In those reports, cough
and dyspnea were also the most common presenting
symptoms.12,14,16 The 50% prevalence of anti-Jo1 antibody
in our series is similar to results in previous series, where it
ranged from 31 to 75%.13e16 We also noted that anti-Jo1
antibody seropositivity correlated strongly with the pres-
ence of mechanic’s hands.
The spectrum of HRCT findings in our patients corre-
sponded with those described in the current literature,17,18
including patterns suggesting primarily NSIP, OP and UIP.
Most patients exhibited imaging features consistent with
more than one pathologic pattern. Although the presence
of an OP pattern has been correlated with better responseto steroids,18,23 it is unknown whether it is also predictive
of response to other therapies. Neither the imaging pattern
nor the extent of fibrosis had not evident correlation with
any of the outcomes, suggesting that therapeutic trials may
be beneficial regardless of the HRCT findings.
Our patients had a range of pathologic patterns, pre-
dominantly NSIP and OP, similar to prior reports.17e19 The
specific pathologic pattern did not appear to correlate with
the treatment response we observed, although the numbers
are too small to provide reliable information. There was
little evident role for bronchoscopy in our population.
The major weakness of this study is that the choice of
immunosuppressive agent was uncontrolled. For example,
it is possible that patients with more severe disease were
treated preferentially with CYC. However, both the radio-
logic and physiologic severity were similar in all three
treatment groups. Another weakness is that the steroid
dose was not reduced in a systemic manner. Our practice is
to routinely attempt to taper prednisone beginning two to
three months after initiating steroid-sparing medications.
Also, this experience does not inform the question of
whether any of these agents should be used as a first line
medication in place of corticosteroids. Finally, the reduc-
tion in dyspnea may relate more to ongoing improvement of
myositis, rather than effects on the ILD. Given the discor-
dance between the relatively unchanged PFTs and the
substantially reduced MMRC Grade, effects on muscle
strength are likely to underlie at least part of this symp-
tomatic benefit.Conclusion
We describe herein the treatment of PM/DM ILD in 46 pa-
tients. To our knowledge, this is the largest case series to
date analyzing the effectiveness of steroid-sparing medi-
cations for PM/DM ILD. We did not find significant outcome
differences between CYC, AZA and MMF, perhaps due to the
small sample size and retrospective nature of this study. In
A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease 895general, treatment with any of these agents was associated
with stabilization of pulmonary physiology, improved dys-
pnea, and a reduction of steroid dose. Given the rarity of
PM/DM ILD, it is unlikely that a randomized trial comparing
these agents will occur soon.Conflict of interest
I do not have any conflict of interest, related with the
manuscript.References
1. Travis W, Colby T, Koss M, Rosado-de Christenson M, Muller NL,
King TE. Non-neoplastic disorders of the lower respiratory
tract. Armed Forces Institute of Pathology First series.
Fascicle 2. 2002:291e310.
2. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Inter-
stitial lung disease associated with the idiopathic inflammatory
myopathies: what progress has been made in the past 35 years?
Chest 2010;138:1464e74.
3. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD,
Furst DE, et al., For the Scleroderma Lung Study Group.
Cyclophosphamide versus placebo in scleroderma lung disease.
New England Journal of Medicine 2006;354(25):2655e66.
4. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL,
et al. A multicenter, prospective, randomized double blind
placebo-controlled trial of corticosteroids and intravenous
cyclophophamide followed by oral azathioprine for the treat-
ment of pulmonary fibrosis in scleroderma. Arthritis & Rheu-
matism 2006;54(12):3962e70.
5. Kobayashi Akiko, Okamoto Hiroshi. Treatment of interstitial
lung diseases associated with connective tissue diseases.
Expert Review of Clinical Pharmacology 2012;5(2):219.
6. Walker DM, Pope J, et al. Treatment of systemic sclerosis
complications: what to use when first line treatment fails ea
consensus of systemic sclerosis experts. Seminars Arthritis &
Rheumatism 2012;42(1):42e55.
7. Miller FW, Rider LG, Plotz PH, Isenberg DA, Oddis CV. Diag-
nostic criteria for polymiositis and dermatomyosits. The Lancet
2003;362:9397.
8. Goh NS, Desai SR, Veeraghavan S, Hansell DM, Copley SJ,
Maher TM, et al. Interstitial lung disease in scleroderma: a
simple staging system. American Journal of Respiratory Crit-
ical Care Medicine 2008;177:1248e54.
9. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference
values from a sample of the general US population (NHANES
III). American Journal of Respiratory Critical Care Medicine
1999;159(1):179e87.
10. Fathi M, Lundberg IE. Interstitial lung disease in polymyositis-
dermatomyositis. Current Opinion in Rheumatology 2005;17:
701e6.
11. Fathi M, et al. Pulmonary complications of polymyositis-der-
matomyositis. Seminars in Respiratory and Critical Care Med-
icine 2007;28(4):451e8.
12. Marie I, Lahace L, Benveniste O, Delavigne K, Adoue D,
Mouthon L, et al. Long-term outcome of patients with
polymyositis-dermatomyositis and anti-pm-Scl antibody.
British of Dermatology 2010;162:337e44.
13. Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY,
Hellot MF, et al. Interstitial lung disease in polymyositis-der-
matomyositis. Arthritis & Rheumatism 2002;47(6):614e22.
14. Douglas WW, Tazelaar HD, Hartman TE, Hartman RB,
Decker PA, Schroeder ER, Ryu JH. Polymiositis-Dermatomyositis associated interstitial lung disease. American
Journal Respiratory Critical Care Medicine 2001;164:1182e5.
15. Selva-O’Collaghan A, Labrador-Horrillo M, Munoz-Gall X, Mar-
tinez-Gomez X, Majo-Masferrer J, et al. PM/DM associated lung
disease: analysis of series of 81 patients. Lupus 2005;14:
534e42.
16. Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Inter-
stitial lung disease in polymyositis-dermatomyositis: clinical
course and response to treatment. Seminars in Arthritis and
Rheumatism 2003;32:273e84.
17. Hayashi S, Tanaka M, Kobayashi H, Nakazono T, Satoh T,
Fukuno Y, et al. HRCT characterization of ILD in PM/DM. The
Journal of Rheumatology 2008;35:260e9.
18. Akira M, Hara H, Sakatani M. Interstitial lung disease in asso-
ciation with polymyositis-dermatomysitis: long-term follow up
CT evaluation in seven patients. Radiology 1999;210(2):
333e8.
19. Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T, Fujit J. Chro-
nological evaluation of the onset of histologically confirmed
interstitial pneumonia associated with polymyositis-dermato-
myosits. Internal Medicine 2002;41:1135e41.
20. Gruhn W, Diaz-Buxo J. Cyclosporine treatment of steroid
resistant interstitial pneumonitis associated with dermatomy-
sitis-polymyositis. J Rheumatology 1987;14:1045e7.
21. Kotani T, Makino S, Takeuchi T, Kagitani M, Shoda T, Hata A,
et al. Early intervention with corticosteroids and cyclosporine-
A and 2-hour post dose blood concentration monitoring im-
proves the prognosis of acute/subacute interstitial pneumonia
in dermatomyositis. Journal of Rheumatology 2008;35:254e9.
22. Koboyashi I, Yamada M, Takahashi Y, Kawamura N, Okano M,
Sakiyama Y, Kobayashi K. Interstitial lung disease associated
with juvenile dermatomyositis: clinical features and efficacy of
cyclosporine A. Rheumatology 2003;43:371e4.
23. Tezelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial
lung disease in polymyositis and dermatomyositis. Clinical
features and prognosis correlated with histology findings.
American Review of Respiratory Disease 1990;141(3):727e33.
24. Yoshida T, Koga H, Saitoh F, Sakamoto M, Harada M, Yoshida H,
et al. Pulse intravenous cyclophosphamide treatment for
steroid-resistant interstitial pneumonitis associated with
polymyositis. Internal Medicine 1999;38:733e8.
25. Shinohara T, Hidaka T, Matsuki Y, Ishizuka T, Takamizawa M,
Kawakami M, et al. Rapidly progressive interstitial lung disease
associated with dermatomyositis responding to intravenous
cyclophosphamide treatment. Internal Medicine 1997;36:
519e23.
26. Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H,
Tokuhira M, et al. Combination treatment with corticosteroids,
cyclosporine A and intravenous pulse of cyclophosphamide for
acute/subacute interstitial pneumonia in patients with der-
matomyositis. Journal of Rheumatology 2005;32:1719e26.
27. Tanaka F, Origuchi T, Migita K, Tominaga M, Kawakami A,
Kawabe Y, Eguchi K. Successful combined therapy of cyclo-
phosphamide for acute exacerbated interstitial pneumonia
associated with dermatomyositis. Internal Medicine 2000;
39(5):428e30.
28. Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K,
Matsuoka S, et al. Intravenous cyclophosphamide treatment
for progressive interstitial pneumonia in patients with poly-
myositis-dermatomyositis. Rheumatology 2007;46:124e30.
29. Mok CC, To CH, Szeto ML. Successful treatment of dermato-
myositis related rapidly progressive interstitial pneumonitis
with sequential oral cyclophosphamide and azathioprine.
Scandinavian Journal of Rheumatology 2003;32:181e3.
30. Swigris JJ, Olson AL, Fisher A, Lynch DA, Cosgrove GP,
Frankel SK, et al. Mycophenolate is safe, well tolerated and
preserves lung function in patients with connective tissue
disease-related interstitial lung disease. Chest 2006;130:30e6.
896 I.C. Mira-Avendano et al.31. Morgannoth PA, Kreider ME, Werth VP, et al. Mycophenolate
mofetil for interstitial lung disease in dermatomyositis.
Arthritis Care & Research 2010;62(10):1496e501.
32. Oddis CV, Sciurba FC, Elmagd KA, Starzi TE. Tacrolimus in re-
fractory polymyositis with interstitial lung disease. The Lancet
1999;353:1762.
33. Takada K, Nagasaka K, Miyasaka N. Therapeutic approach with
T-cell-specific immunosuppesants. Autoimmunity 2005;38(5):
383e92.
34. Ochi S, Nanki K, Takada K, Suzuki F, Komano Y, Kubota T,
Miyasaka N. Favorable outcomes with tacrolimus in two pa-
tients with refractory interstitial lung disease associated withpolymyositis-dermatomyositis. Clinical and Experimental
Rheumatology 2005;23:707e10.
35. Lange U, Piegsa M, Muller-Ladner U, Strunk J. Anti-Jo1 positive
polymyositis. Successful therapy with leflunomide. Autoim-
munity 2006;39(3):261e4.
36. Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H,
Suda T, Chida K. Intravenous immunoglobulin therapy for re-
fractory interstitial lung disease associated with polymyositis
and dermatomyositis. Lung 2009;187:201e6.
37. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of
the anti-synthetase syndrome. A retrospective case series.
Rheumatology 2009;48:968e71.
